# US 6,726,928 B2 · Process for preparing solid dosage forms for unpalatable pharmaceuticals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,726,928 B2
- Document ID: US6726928B2
- Status: Granted
- Kind: B2
- Application number: 09/551,361
- Filed: 2000-04-18
- Published: 2002-10-03
- Granted: 2004-04-27
- Earliest claimed: 1994-10-28
- Assignees: R.P. Scherer Technologies, LLC
- Inventors: Richard J. Yarwood; Patrick Kearney; Andrew R. Thompson
- Web page: https://patentgrep.com/patent/US6726928B2

## CPC

- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A process for the preparation of a rapidly disintegrating dosage form a pharmaceutically active substance which has an unacceptable taste wherein there is formed a solution or a suspension in a solvent of a form of the pharmaceutically active substance which is less soluble in water and more palatable than the form with the unacceptable taste together with a water-soluble or water-dispersible carrier material. Discrete units of the suspension or solution are formed and the solvent is removed from the discrete units under conditions whereby a network of the carrier material carrying a dosage for the less soluble and more palatable form of the pharmaceutically active substance is formed.

## Claims

### Claim 1

A process for the preparation of a solid, oral, rapidly disintegrating dosage form of a pharmaceutically active substance which has an unacceptable taste, which process comprises:
a) forming a system selected from the group consisting of a solution and a suspension in an aqueous or alcoholic solvent of a form of the pharmaceutically active substance which is rendered less soluble by a method selected from the group consisting of conversion of a salt to a corresponding free acid, conversion of a salt to a corresponding free base, changing the salt form, formation of a hydrate and changing the polymorphic form thereof; together with a carrier material selected from the group consisting of water-soluble and water-dispersible carrier materials;
b) forming discrete units of the system; and
c) removing the solvent from the discrete units under conditions whereby a network of the carrier material carrying a dosage of the less soluble and more palatable form of the pharmaceutically active substance is formed.

### Claim 2 (depends on 1)

The process according to claim 1 wherein the pharmaceutically active substance with the unacceptable taste is presented in a less soluble form prior to formation of said system.

### Claim 3 (depends on 1)

The process according to claim 1 wherein the pharmaceutically active substance with the unacceptable taste is converted into a less soluble form during the preparation of the system.

### Claim 4 (depends on 1)

The process according to claim 1 wherein the carrier material is gelatin.

### Claim 5 (depends on 1)

The process according to claim 1 wherein the discrete units are selected from the group consisting of liquid, frozen and gelled units.

### Claim 6 (depends on 5)

The process according to claim 5 wherein the discrete units are formed in a mold comprising a plurality of pockets.

### Claim 7 (depends on 5)

The process according to claim 5 wherein the discrete units are liquid units which are frozen prior to removal of the solvent.

### Claim 8 (depends on 5)

The process according to claim 5 wherein the units are frozen units and the solvent is removed by freeze drying.

### Claim 9 (depends on 5)

The process according to claim 5 wherein said units are frozen liquid units and said solvent is removed by vacuum drying under conditions whereby the solvent is evaporated from said frozen units through the liquid phase to a gas.

### Claim 10 (depends on 5)

The process according to claim 5 wherein the discrete units are gelled units from which the solvent is removed by drying under conditions selected from the group consisting of decreased pressure and forced-air drying.

### Claim 11 (depends on 6)

The process according to claim 6 wherein the mold comprises at least one depression in a sheet of a filmic material.

### Claim 12 (depends on 11)

The process according to claim 11 wherein a sheet of a covering material is adhered to a filmic material in the area around at least one said depression after the removal of solvent from said system.

### Claim 13 (depends on 1)

The process according to claim 1 wherein the pharmaceutically active substance is loperamide hydrochloride which is converted into the form of the loperamide free base during the preparation of the system.

### Claim 14 (depends on 1)

The process according to claim 1 wherein the less soluble pharmaceutically active substance is free domperidone base.

### Claim 15 (depends on 1)

A solid, oral, rapidly disintegrating dosage form of a pharmaceutically active substance prepared by a process according to claim 1.

### Claim 16 (depends on 15)

A solid, oral, rapidly disintegrating dosage form according to claim 15 wherein the pharmaceutically active is loperamide which is present in the composition in the form of the loperamide free base.

### Claim 17

A solid, oral, rapidly disintegrating dosage form comprising loperamide free base as the pharmaceutically active substance in a network of a carrier material selected from the group consisting of water-soluble and water-dispersible carrier materials.
